195 related articles for article (PubMed ID: 32219444)
21. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.
Quentmeier H; Eberth S; Romani J; Zaborski M; Drexler HG
J Hematol Oncol; 2011 Feb; 4():6. PubMed ID: 21299849
[TBL] [Abstract][Full Text] [Related]
22. AhR ligand aminoflavone suppresses α6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells.
Campbell PS; Mavingire N; Khan S; Rowland LK; Wooten JV; Opoku-Agyeman A; Guevara A; Soto U; Cavalli F; Loaiza-Pérez AI; Nagaraj G; Denham LJ; Adeoye O; Jenkins BD; Davis MB; Schiff R; Brantley EJ
J Cell Physiol; 2018 Jan; 234(1):108-121. PubMed ID: 30076704
[TBL] [Abstract][Full Text] [Related]
23. PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells.
Wu N; Kurosu T; Oshikawa G; Nagao T; Miura O
Int J Oncol; 2013 Feb; 42(2):419-28. PubMed ID: 23233201
[TBL] [Abstract][Full Text] [Related]
24. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells.
Klein F; Feldhahn N; Herzog S; Sprangers M; Mooster JL; Jumaa H; Müschen M
Oncogene; 2006 Feb; 25(7):1118-24. PubMed ID: 16205638
[TBL] [Abstract][Full Text] [Related]
25. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R
Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118
[TBL] [Abstract][Full Text] [Related]
26. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.
Mahon FX; Hayette S; Lagarde V; Belloc F; Turcq B; Nicolini F; Belanger C; Manley PW; Leroy C; Etienne G; Roche S; Pasquet JM
Cancer Res; 2008 Dec; 68(23):9809-16. PubMed ID: 19047160
[TBL] [Abstract][Full Text] [Related]
27. SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
Gu S; Sayad A; Chan G; Yang W; Lu Z; Virtanen C; Van Etten RA; Neel BG
Leukemia; 2018 Jan; 32(1):203-213. PubMed ID: 28804122
[TBL] [Abstract][Full Text] [Related]
28. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
29. Integrin subunits alpha5 and alpha6 regulate cell cycle by modulating the chk1 and Rb/E2F pathways to affect breast cancer metastasis.
Wang Y; Shenouda S; Baranwal S; Rathinam R; Jain P; Bao L; Hazari S; Dash S; Alahari SK
Mol Cancer; 2011 Jul; 10():84. PubMed ID: 21752283
[TBL] [Abstract][Full Text] [Related]
30. Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network.
Uckun FM; Qazi S; Ozer Z; Garner AL; Pitt J; Ma H; Janda KD
Br J Haematol; 2011 Jun; 153(6):741-52. PubMed ID: 21517817
[TBL] [Abstract][Full Text] [Related]
31. Beta1 integrin blockade overcomes doxorubicin resistance in human T-cell acute lymphoblastic leukemia.
Berrazouane S; Boisvert M; Salti S; Mourad W; Al-Daccak R; Barabé F; Aoudjit F
Cell Death Dis; 2019 May; 10(5):357. PubMed ID: 31043590
[TBL] [Abstract][Full Text] [Related]
32. Targeting of BCR-ABL1 and IRE1α induces synthetic lethality in Philadelphia-positive acute lymphoblastic leukemia.
Vieri M; Preisinger C; Schemionek M; Salimi A; Patterson JB; Samali A; Brümmendorf TH; Appelmann I; Kharabi Masouleh B
Carcinogenesis; 2021 Feb; 42(2):272-284. PubMed ID: 32915195
[TBL] [Abstract][Full Text] [Related]
33. α6 integrin subunit regulates cerebellar development.
Marchetti G; De Arcangelis A; Pfister V; Georges-Labouesse E
Cell Adh Migr; 2013; 7(3):325-32. PubMed ID: 23722246
[TBL] [Abstract][Full Text] [Related]
34. Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia.
de Groot AP; Saito Y; Kawakami E; Hashimoto M; Aoki Y; Ono R; Ogahara I; Fujiki S; Kaneko A; Sato K; Kajita H; Watanabe T; Takagi M; Tomizawa D; Koh K; Eguchi M; Ishii E; Ohara O; Shultz LD; Mizutani S; Ishikawa F
EBioMedicine; 2021 Feb; 64():103235. PubMed ID: 33581643
[TBL] [Abstract][Full Text] [Related]
35. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Ottmann OG; Pfeifer H
Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
[TBL] [Abstract][Full Text] [Related]
36. Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells.
Svensson E; Vidovic K; Lassen C; Richter J; Olofsson T; Fioretos T; Gullberg U
Leukemia; 2007 Dec; 21(12):2485-94. PubMed ID: 17728783
[TBL] [Abstract][Full Text] [Related]
37. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Hu Y; Liu Y; Pelletier S; Buchdunger E; Warmuth M; Fabbro D; Hallek M; Van Etten RA; Li S
Nat Genet; 2004 May; 36(5):453-61. PubMed ID: 15098032
[TBL] [Abstract][Full Text] [Related]
38. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.
Fei F; Stoddart S; Müschen M; Kim YM; Groffen J; Heisterkamp N
Leukemia; 2010 Apr; 24(4):813-20. PubMed ID: 20111071
[TBL] [Abstract][Full Text] [Related]
39. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
Yokota A; Kimura S; Masuda S; Ashihara E; Kuroda J; Sato K; Kamitsuji Y; Kawata E; Deguchi Y; Urasaki Y; Terui Y; Ruthardt M; Ueda T; Hatake K; Inui K; Maekawa T
Blood; 2007 Jan; 109(1):306-14. PubMed ID: 16954504
[TBL] [Abstract][Full Text] [Related]
40. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
Eiring AM; Page BDG; Kraft IL; Mason CC; Vellore NA; Resetca D; Zabriskie MS; Zhang TY; Khorashad JS; Engar AJ; Reynolds KR; Anderson DJ; Senina A; Pomicter AD; Arpin CC; Ahmad S; Heaton WL; Tantravahi SK; Todic A; Moriggl R; Wilson DJ; Baron R; O'Hare T; Gunning PT; Deininger MW
Leukemia; 2015 Mar; 29(3):586-597. PubMed ID: 25134459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
